Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 1/2015

Open Access 01-02-2015 | Review

Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine

Authors: Daniel Shouval, Hedwig Roggendorf, Michael Roggendorf

Published in: Medical Microbiology and Immunology | Issue 1/2015

Login to get access

Abstract

Efficacy and safety of recombinant yeast-derived hepatitis B vaccines for prevention of hepatitis B have been demonstrated unequivocally worldwide as reflected in reduction in HBsAg carrier rates and hepatocellular carcinoma. A new generation of recombinant HBV vaccines expressed in mammalian cells containing Pre-S/S epitopes has been developed in several countries. Such vaccines are useful in special risk groups, i.e., in non-responders to conventional HBV vaccines including older adults, obese people, health care workers, patients with renal failure and on dialysis, transplant patients, patients with HIV as well as travelers on short notice to HBV endemic regions. The future of such vaccines depends on their enhanced immunogenicity and cost profile. Sci-B-Vac™ is a mammalian cell-derived recombinant Pre-S1/Pre-S2/S hepatitis B vaccine which has been shown to be highly immunogenic, inducing faster and higher seroprotection rates against HBV with higher anti-HBs levels at lower HBsAg doses as compared to conventional yeast-derived vaccines. Recently, it has been suggested that such Pre-S/S vaccines against HBV might be efficacious not only for prevention but also for intervention in persistent HBV infection. Data obtained in a recent clinical trial conducted in Vietnam in patients with chronic hepatitis B suggest that repeated monthly i.m. injections of the Sci-B-Vac™ co-administered with daily oral lamivudine treatment can suppress HBV replication and lead to anti-HBs seroconversion in ~50 % of treated patients. Optimization of protocols and efficacy of such an intervention, intended to bypass T cell exhaustion and immune tolerance to HBV remains to be explored.
Literature
1.
Zanetti AR, Van Damme P, Shouval D (2008) The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26:6266–6273PubMedCrossRef
2.
3.
Zuckerman JN, Zuckerman AJ, Symington I, Du W, Williams A, Dickson B, Young MD (2001) Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines. Hepatology 34:798–802PubMedCrossRef
4.
Yum JS, Ahn BC, Jo HJ, Kim DY, Kim KH, Kim HS, Sung YC, Yoon J, Morrey J, Moon HM (2012) Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection. Clin Vaccine Immunol 19:120–127PubMedCentralPubMedCrossRef
5.
Pol S, Nalpas B, Driss F, Michel ML, Tiollais P, Denis J, Brecho C (2001) Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 34:917–921PubMedCrossRef
6.
Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH (1994) Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12:1453–1459PubMedCrossRef
7.
Kubba AK, Taylor P, Graneek B, Strobel S (2003) Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 6:106–112PubMed
8.
Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G (2004) Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 20:1053–1062PubMedCrossRef
9.
Laurence JC (2005) Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med 118(Suppl 10A):75S–83SPubMedCrossRef
10.
Aziz A, Aziz S, Li DS, Murphy L, Leone N, Kennedy M, Dhillon S, Van Thiel DH (2006) Efficacy of repeated high-dose hepatitis B vaccine (80 microg) in patients with chronic liver disease. J Viral Hepat 13:217–221PubMedCrossRef
11.
Fabrizi F, Dixit V, Bunnapradist S, Martin P (2006) Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population. Aliment Pharmacol Ther 23:1105–1112PubMedCrossRef
12.
Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH (2009) Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 20:595–600PubMedCrossRef
13.
Alavian SM, Tabatabaei SV (2010) The effect of diabetes mellitus on immunological response to hepatitis B virus vaccine in individuals with chronic kidney disease: a meta-analysis of current literature. Vaccine 28:3773–3777PubMedCrossRef
14.
Gisbert JP, Chaparro M, Esteve M (2011) Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 33:619–633PubMedCrossRef
15.
Fabrizi F, Dixit V, Martin P, Jadoul M, Messa P (2012) Meta-analysis: the impact of nutritional status on the immune response to hepatitis B virus vaccine in chronic kidney disease. Dig Dis Sci 57:1366–1372PubMedCrossRef
16.
Vitaliti G, Pratico AD, Cimino C, Di Dio G, Lionetti E, La Rosa M, Leonardi S (2013) Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow. World J Gastroenterol 19:838–845PubMedCentralPubMedCrossRef
17.
Kamath GR, Shah DP, Hwang LY (2014) Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine 32:2265–2274PubMedCrossRef
18.
Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, Brink SJ, Dienstag JL, Awdeh Z, Yunis EJ (1989) Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321:708–712PubMedCrossRef
19.
Li ZK, Nie JJ, Li J, Zhuang H (2013) The effect of HLA on immunological response to hepatitis B vaccine in healthy people: a meta-analysis. Vaccine 31:4355–4361PubMedCrossRef
20.
Milich DR, Hughes JL, Mclachlan A, Thornton GB, Moriarty A (1988) Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope. Proc Natl Acad Sci USA 85:1610–1614PubMedCentralPubMedCrossRef
21.
Itoh Y, Takai E, Ohnuma H, Kitajima K, Tsuda F, Machida A, Mishiro S, Nakamura T, Miyakawa Y, Mayumi M (1986) A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: protective efficacy in chimpanzees. Proc Natl Acad Sci USA 83:9174–9178PubMedCentralPubMedCrossRef
22.
Leroux-Roels G, Desombere I, De Tollenaere G, Petit MA, Desmons P, Hauser P, Delem A, De Grave D, Safary A (1997) Hepatitis B vaccine containing surface antigen and selected preS1 and preS2 sequences. 1. Safety and immunogenicity in young, healthy adults. Vaccine 15:1724–1731PubMedCrossRef
23.
Fujisawa Y, Kuroda S, Van Eerd PM, Schellekens H, Kakinuma A (1990) Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine 8:192–198PubMedCrossRef
24.
Sanyal G, Shi L (2009) A review of multiple approaches towards an improved hepatitis B vaccine. Expert Opin Ther Pat 19:59–72PubMedCrossRef
25.
Pollicino T, Cacciola I, Saffioti F, Raimondo G et al. (2014) Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 61:408–417PubMedCrossRef
26.
Zuckerman JN (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169–177PubMedCrossRef
27.
Laub O, Rall LB, Truett M, Shaul Y, Standring DN, Valenzuela P, Rutter WJ (1983) Synthesis of hepatitis B surface antigen in mammalian cells: expression of the entire gene and the coding region. J Virol 48:271–280PubMedCentralPubMed
28.
Madalinski K, Sylvan SP, Hellstrom U, Mikolajewicz J, Zembrzuska-Sadkowska E, Piontek E (2001) Antibody responses to preS components after immunization of children with low doses of BioHepB. Vaccine 20:92–97PubMedCrossRef
29.
Hellstrom UB, Madalinski K, Sylvan SP (2009) PreS1 epitope recognition in newborns after vaccination with the third-generation Sci-B-Vac vaccine and their relation to the antibody response to hepatitis B surface antigen. Virol J 6:7PubMedCentralPubMedCrossRef
30.
Sylvan SP, Madalinski K, Hellstrom UB (2009) Anti-preS responses influence the anti-HBs response in newborns after vaccination with the third generation Sci-B-Vac vaccine. Vaccine 28:446–451PubMedCrossRef
31.
Diminsky D, Schirmbeck R, Reimann J, Barenholz Y (1997) Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 15:637–647PubMedCrossRef
32.
Diminsky D, Moav N, Gorecki M, Barenholz Y (1999) Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18:3–17PubMedCrossRef
33.
Yap I, Guan R, Chan SH (1992) Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein—a preliminary study on immunogenicity. Vaccine 10:439–442PubMedCrossRef
34.
Yap I, Guan R, Chan SH (1995) Study on the comparative immunogenicity of a recombinant DNA hepatitis B vaccine containing pre-S components of the HBV coat protein with non pre-S containing vaccines. J Gastroenterol Hepatol 10:51–55PubMedCrossRef
35.
Hourvitz A, Mosseri R, Solomon A, Yehezkelli Y, Atsmon J, Danon YL, Koren R, Shouval D (1996) Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. J Viral Hepat 3:37–42PubMedCrossRef
36.
Yerushalmi B, Raz R, Blondheim O, Shumov E, Koren R, Dagan R (1997) Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Pediatr Infect Dis J 16:587–592PubMedCrossRef
37.
Shapira MY, Zeira E, Adler R, Shouval D (2001) Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine. J Hepatol 34:123–127PubMedCrossRef
38.
Raz R, Dagan R, Gallil A, Brill G, Kassis I, Koren R (1996) Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Vaccine 14:207–211PubMedCrossRef
39.
Weinstein T, Chagnac A, Boaz M, Ori Y, Herman M, Zevin D, Schmilovitz-Weiss H, Gafter U (2004) Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin Pract 97:c67–c72PubMedCrossRef
40.
Wilson JN, Nokes DJ, Medley GF, Shouval D (2007) Mathematical model of the antibody response to hepatitis B vaccines: implications for reduced schedules. Vaccine 25:3705–3712PubMedCrossRef
41.
Schumann A, Fiedler M, Dahmen U, Grosse-Wilde H, Roggendorf M, Lindemann M (2007) Cellular and humoral immune response to a third generation hepatitis B vaccine. J Viral Hepat 14:592–598PubMedCrossRef
42.
Rendi-Wagner P, Shouval D, Genton B, Lurie Y, Rumke H, Boland G, Cerny A, Heim M, Bach D, Schroeder M, Kollaritsch H (2006) Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24:2781–2789PubMedCrossRef
43.
Yap I, Chan SH (1996) A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Ann Acad Med Singapore 25:120–122PubMed
44.
Lo CM, Lau GK, Chan SC, Fan ST, Wong J (2007) Efficacy of a pre-S containing vaccine in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. Am J Transplant 7:434–439PubMedCrossRef
45.
Krawczyk A, Roggendorf H, Ludwig C, Herzer K, Gerken G, Horn PA, Roggendorf M, Lindemann M (2013) Therapeutic vaccination of a liver transplant recipient suffering from fulminant hepatitis B during pregnancy. Liver Transplant 19:1411–1412CrossRef
46.
Shouval D, Adler R, Ilan Y (1993) Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. Hepatology 17:955–959PubMedCrossRef
47.
Dahmen U, Li J, Gu Y, Doebel L, Fan LM, Polywka S, Dirsch O, Broelsch CE (2003) The efficiency of humoral immune transfer depends on both the graft and the immunosuppressive treatment. Transpl Int 16:161–167PubMedCrossRef
48.
Dahmen U, Dirsch O, Li J, Fiedle M, Lu M, Rispeter K, Picucci M, Broelsch CE, Roggendorf M (2004) Adoptive transfer of immunity: a new strategy to interfere with severe hepatitis virus reinfection after woodchuck liver transplantation. Transplantation 77:965–972PubMedCrossRef
49.
Ilan Y, Nagler A, Adler R, Tur-Kaspa R, Slavin S, Shouval D (1993) Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 104:1818–1821PubMed
50.
Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, Lam SK (1997) Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 25:1497–1501PubMedCrossRef
51.
Lau GK, Suri D, Liang R, Rigopoulou EI, Thomas MG, Mullerova I, Nanji A, Yuen ST, Williams R, Naoumov NV (2002) Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 122:614–624PubMedCrossRef
52.
Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J (2007) Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transplant 13:71–79CrossRef
53.
Schumann A, Lindemann M, Valentin-Gamazo C, Lu M, Elmaagacli A, Dahmen U, Knop D, Broelsch CE, Grosse-Wilde H, Roggendorf M, Fiedler M (2009) Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 87:103–111PubMedCrossRef
54.
Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 2:1104–1108PubMedCrossRef
55.
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W (2012) Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049PubMedCentralPubMedCrossRef
56.
Urban S, Bartenschlager R, Kubitz R, Zoulim F (2014) Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology  147:48–64PubMedCrossRef
57.
Bertoletti A, Ferrari C (2012) Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 61:1754–1764PubMedCrossRef
58.
Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, Michel ML (1999) Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 180:15–26PubMedCrossRef
59.
Horiike N, Akbar SMF, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, Onji M (2005) In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol 32:156–161PubMedCrossRef
60.
Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ (1995) Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 345:1575–1576PubMedCrossRef
61.
Wen Y, Wang X, Wang B, Yuan Z (2014) Vaccine therapies for chronic hepatitis B: can we go further? Front Med 8:17–23PubMedCrossRef
62.
Heathcote J, Mchutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R (1999) A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 30:531–536PubMedCrossRef
63.
Fontaine H, Kahi S, Chazallon C, Bourgine M, Varaut A, Buffet C, Godon O, Meritet JF, Saidi Y, Michel ML, Scott-Algara D, Aboulker JP, Pol S (2015) Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial–ANRS HB02 VAC-ADN. Gut 64:139–147
64.
Michel ML, Mancini-Bourgine M (2005) Therapeutic vaccination against chronic hepatitis B virus infection. J Clin Virol 34(Suppl 1):S108–S114PubMedCrossRef
65.
Michel ML, Deng Q, Mancini-Bourgine M (2011) Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 54:1286–1296PubMedCrossRef
66.
Roggendorf M, Schulte I, Xu Y, Lu M (2007) Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model. J Viral Hepat 14(Suppl 1):51–57PubMedCrossRef
67.
Inchauspe G, Bach G, Martin P, Bonnefoy JY (2009) Vaccination against hepatitis B and C: towards therapeutic application. Int Rev Immunol 28:7–19PubMedCrossRef
68.
Liu J, Kosinska A, Lu M, Roggendorf M (2014) New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol Sin 29:10–16PubMedCrossRef
69.
Bertoletti A, Gehring A (2009) Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev Gastroenterol Hepatol 3:561–569PubMedCrossRef
70.
Eng NF, Bhardwaj N, Mulligan R, Diaz-Mitoma F (2013) The potential of 1018 ISS adjuvant in hepatitis B vaccines: HEPLISAV review. Hum Vaccin Immunother 9:1661–1672PubMedCentralPubMedCrossRef
71.
Pol S, Driss F, Michel ML, Nalpas B, Berthelot P, Brechot C (1994) Specific vaccine therapy in chronic hepatitis B infection. Lancet 344:342PubMedCrossRef
72.
Dikici B, Kalayci AG, Ozgenc F, Bosnak M, Davutoglu M, Ece A, Ozkan T, Ozeke T, Yagci RV, Haspolat K (2003) Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection. Pediatr Infect Dis J 22:345–349PubMed
73.
Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, Furutani M, Yamasaki T, Korenaga K, Yamashita S, Konishi T, Okita K (2003) Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol 71:376–384PubMedCrossRef
74.
Vandepapeliere P, Lau GK, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican MI, Win KM, Trepo C, Cooksley G, Wettendorff M, Ferrari C (2007) Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25:8585–8597PubMedCrossRef
75.
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Yuan ZH, Wang B, Zhao K, Wen YM (2013) Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol 59:450–456PubMedCrossRef
76.
Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, Alfieri A, Pesci M, Gaeta GB, Brancaccio G, Colombo M, Missale G, Ferrari C (2012) Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 143(963–73):e9PubMed
77.
Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, Ferrari C (1998) Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 102:968–975PubMedCentralPubMedCrossRef
78.
Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, Ferrari C (2003) Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 39:595–605PubMedCrossRef
79.
Gotsman I, Beinart R, Alper R, Rabbani E, Engelhardt D, Ilan Y (2000) Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. Antiviral Res 48:17–26PubMedCrossRef
80.
Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N, Segol O, Thalenfeld B, Engelhardt D, Rabbani E, Ilan Y (2003) Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 98:2505–2515PubMedCrossRef
81.
Hoa PT, Huy NT, Le Thu T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K (2009) Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 53:5134–5140PubMedCentralPubMedCrossRef
82.
Metadata
Title
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S Vaccine
Authors
Daniel Shouval
Hedwig Roggendorf
Michael Roggendorf
Publication date
01-02-2015
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 1/2015
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-014-0374-x

Other articles of this Issue 1/2015

Medical Microbiology and Immunology 1/2015 Go to the issue

Review

Therapeutic vaccines in HBV: lessons from HCV

Review

Therapeutic vaccines in treating chronic hepatitis B: the end of the beginning or the beginning of the end?

Review

Natural history of chronic hepatitis B virus infection

Review

Electroporation for therapeutic DNA vaccination in patients

Review

Antiviral therapy for chronic hepatitis B in China

Review

Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits